Guiding Principles on the Sharing of Clinical Trial Data. DNDi POLICIES

Similar documents
Joint statement on public disclosure of results from clinical trials

Data & Materials Sharing Agreement. Collaboration for AIDS Vaccine Discovery. Clinical Trials Data Sharing Addendum & Related Information

EFPIA-PHRMA PRINCIPLES FOR RESPONSIBLE CLINICAL TRIAL DATA SHARING REPORT ON THE 2016 MEMBER COMPANY SURVEY

COVER PAGE. Title: Regulatory Implications of Data-mining Author: Renee Harrell Word Count: 2387 COVER PAGE

CONSTITUTION OF THE GLOBAL ALLIANCE FOR GENOMICS AND HEALTH. Adopted, 2014

How is trial registration affecting gjournals?

CODE OF PRACTICE FOR RESEARCH

Governance Policies for PCORnet, the National Patient-Centered Clinical Research Network

Revision of Helsinki Declaration

Child and Family Agency. Research Ethics Committee Guidelines

WCG ACADEMY COURSE OVERVIEW

The Yale Open Data Access (YODA) Project: Lessons Learned in Data Sharing

Ethical Governance Framework

Ethics Committees/IRBs Today: Challenges for Efficiency and Quality

TOP 10 INVESTIGATOR RESPONSIBILITIES WHEN CONDUCTING HUMAN SUBJECTS RESEARCH

Investigator Conflict of Interest Disclosure Policy for Human Subjects Research

Not My Study Challenges of Clinical Trial Disclosure at an Academic Medical Center

Draft proposal for an addendum, on transparency, to the Functional specifications for the EU portal and EU database to be audited - EMA/42176/2014

Research Ethics Governance Policy

DATA SHARING AGREEMENT

Ethical Principles in Clinical Research

Trends in Oversight of Human Research Protections?

Journal of Clinical Urology (JCU): Declaration Guidelines for Authors

Biomedical Research on Human Participants

Longitudinal Population Studies Strategy

Human Subjects Protection: Training for Research Teams

INVESTIGATIONAL DEVICE EXEMPTION APPLICATION. IDE Title (if title being used)

WMA Declaration of Helsinki - Ethical

10/9/2012. Alicia Joy, IRB. Wednesday October 10, Please be sure to sign in and take copies of each handout.

World Medical Association Declaration of Helsinki

IRB-GCP and Timelines. Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October th, 2010

Good Clinical Practice (GCP) & Clinical Trial Registries

Recommendation on elements required to support the medical plausibility and the assumption of significant benefit for an orphan designation

What is an IRB (Institutional Review Board)?

Policy Position. Pharmacy-mediated interchangeability for Similar Biotherapeutic Products (SBPs)

Institutional Review Board for Use of Human and Animal Subjects in Research OIT

New Pharmacovigilance legislation. Post-authorisation safety studies. ENCePP Plenary meeting. 3 May 2012

Research Involving Human Data or Specimens

Institutional Review Board for the Protection of Human Subjects

Guideline on good pharmacovigilance practices (GVP)

Technical Guidance on Clinical Evaluation of Medical Devices

Trial oversight SOP for HEY-sponsored CTIMPs

Acting Deputy Commissioner for Operations, U.S. Food and Drug Administration

Fergus Sweeney, European Medicines Agency

Hospital Authority (HA) Guide on Research Ethics (for Study Site & Research Ethics Committee)

Application form UNIVERSITY OF NOTTINGHAM MEDICAL SCHOOL ETHICS COMMITTEE

Canadian Longitudinal Study on Aging (CLSA) Data and Biospecimen Access Policy and Guiding Principles

GUIDELINE REGARDING COLLECTION, VERIFICATION, AND SUBMISSION OF THE REPORTS OF ADVERSE EVENTS / REACTIONS OCCURRING IN CLINICAL DRUG TRIALS

Rules of Human Experimentation

PHARMA CONGRESS. Pharmacovigilance and Drug Safety: Assessing Future Regulatory and Compliance Developments. October 28, 2008

07/30/2013. Record of Revisions IRB Page 1 of 17

Reflection paper on guidance for laboratories that perform the analysis or evaluation of clinical trial samples

NIH Policy on the Dissemination of NIH-Funded Clinical Trial Information

Ethical, Legal and Social Issues arising out of Advancements in New Biology. Seyed E. Hasnain

Public release of clinical information in drug submissions and medical device applications

MRC. Clinical Trials. Series MRC GUIDELINES FOR GOOD CLINICAL PRACTICE IN CLINICAL TRIALS. Medical Research Council

Sponsorship of Clinical Research Studies

A notice on the issuance of drug clinical trials, ethical review of the guiding principles

Long-Term Follow-Up in Gene Transfer Clinical Research

THE GULF COAST CENTER CORPORATE COMPLIANCE PLAN

AACT-Results: The Results dataset extensions for the AACT database

Project Management Standards Applied to Complex Clinical Trials. Disclaimer

Confirming Research Study Capacity and Capability

Pre-Screening revised checklist for BA/BE NOC for Export Purpose

S A I N T M A RY S E M I N A RY O C T O B E R 1 9,

Ethical Principles in Clinical Research. Disclaimer. Christine Grady Department of Bioethics NIH Clinical Center

ISPE Comments on the CIOMS 2006 draft Special Ethical Considerations for Epidemiologic Research 1

Research: Ethics, Informed Consent, FDA, Off Label Use

Primary Care mcta 2013: Guidance for use

CLINICAL TRIALS AND MARKET RESEARCH

CEPI Coalition for Epidemic Preparedness Innovations. CEPI a model for funding other initiatives and areas

FDA > CDRH > CFR Title 21 Database Search

Publicly Funded Clinical Trials: A Route to Sustained Innovation with Affordable Drugs

Munafò, M. R. (2016). Opening up addiction science. Addiction, 111(3), DOI: /add.13147

annex 3. Template consent form for biobanking

RESEARCH GOVERNANCE SITE SPECIFIC ASSESSMENT

GCP Basics - refresher

Protocol for Developing Multi-Stakeholder Group Terms of Reference and Internal Governance Rules and Procedures

Environmental Scan Process

Office for Human Subject Protection. University of Rochester

APPLICATION INSTRUCTIONS INSTITUTIONAL REVIEW BOARD. Revised January 2010 Page 1

Doing Human Subjects Research? Changing NIH Policies May Impact You

ClinicalTrials.gov Registration Guide

December 4, Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852

Canadian Task Force on Preventive Health Care Procedure Manual

University of New Mexico Health Sciences Center Office of Research Policy for the Oversight of Human Tissue in Research

PERSONALISED MEDICINE FOR THE BENEFIT OF PATIENTS

Conflict of Interest Disclosure Form

Mini Summit IV: Advanced Issues in Transparency and Disclosure - Research and Clinical Trials Update

Guidance for Industry and FDA Staff Procedures for Handling Post-Approval Studies Imposed by PMA Order

Radiation - Florida Department of Health Institutional Review Board

SHRINERS HOSPITALS FOR CHILDREN CORPORATE COMPLIANCE PLAN

Review of EU Clinical Trial Directive. 15 May 2012 Mike Beckers Sidley Austin LLP, Brussels

NSWTA BOARD DECLARATION

Reconsidering the Ethical Permissibility of the use of Unregistered Interventions against Ebola Virus Disease

STANDARD OPERATING PROCEDURE SOP 310

Canadian Cancer Clinical Trials Network Portfolio Eligibility Criteria and Guidelines

Comparison of admission rates to neonatal units between PO screening and non-po screening Units

Transcription:

Guiding Principles on the Sharing of Clinical Trial Data DNDi POLICIES May 2017

I. Preamble DNDi s vision is to improve the quality of life and health of people suffering from neglected tropical diseases by using an alternative model to develop drugs for these diseases, and by ensuring equitable access to new and field-relevant health tools. DNDi recognizes the potential value, to researchers in public health and other actors, of the data gathered in the course of its research and development activities. DNDi also recognizes the ethical imperative to share and disseminate its data responsibly in order to contribute to knowledge for the improvement of lives of neglected patients whose needs are often overlooked as research priorities. II. Scope This document applies to all final (locked and analyzed) and anonymized patient-level data and clinical study reports on all clinical trials, Phase I trials, where DNDi as Sponsor owns the generated data. When DNDi is involved in a study in the capacity other than as the Sponsor, as a cosponsor, DNDi will make efforts to have these principles followed by the third parties. III. Guiding principles DNDi commits to sharing its clinical trial data in a manner that respects the following principles: The respect of participants in medical research: Through informed consent documents and other procedures as part of a protocol at the outset of clinical research, DNDi will ensure medical confidentiality is fully protected, and the privacy of individuals and the dignity of communities is fully respected when data is collected and, thereafter, shared. Patients will have the rights to refuse data sharing. In order to lessen the risk of identification of individuals, especially in the case of rare indications or subgroups where standard anonymization could be perceived as insufficient, DNDi will consider implementing additional methods to ensure data remains anonymous. Maximizing the benefits to participants and society, while minimizing any potential harm: DNDi aims to share its data in order to facilitate, thanks to greater transparency, both the validation of scientific and research results ( negative results), as well as the contribution by other researchers to the creation of additional knowledge. DNDi will seek to ensure the sharing of data balances the needs of researchers who generate data, researchers who may wish to re-use the data, and the individuals and communities who participated in health research in the expectation of it leading to broader public health benefits. DNDi will seek to minimize potential harm from data sharing, privacy invasion, biased analyses, unfair and competitive use of data, and the undermining of public trust in and incentives to conduct clinical trials. Page 1

IV. Timing and procedures Prior to data collection: Before data collection, clinical trials sponsored by DNDi are registered on public databases such as the US NIH s clinicaltrials.gov or the Pan-African Clinical Trials Registry (PACTR). Before data collection, DNDi will also publish on its global website (dndi.org) the synopsis of clinical trial protocols. Completion of study and prior to publication of results: Prior to publication and after study completion, data sharing will be available on a request basis for research projects, based on a final and cleaned database. Requests for access will be examined by DNDi s Scientific Advisory Committee. Criterion to be used by the Scientific Advisory Committee to determine the validity of requests for access to DNDi data include the scientific justification of the request, compliance by the requesting party with ethical considerations, and a commitment from the requesting party to share with DNDi and publish the results of the follow-on research. In addition, the applicant will commit to acknowledge the source of data. DNDi will post key results of the research 12 months after completion of the trial. Upon publication of study results: DNDi will publish its studies, whether results are positive or negative, in open-access peerreviewed journals. Data will be shared upon publication of study results, in line with the procedures of major medical journals Nature, PLOS, BMJ, etc. V. Implementation The DNDi Executive Director will ensure the full implementation of this document and put in place, subject where appropriate to Board approval, administrative, financial, technical, and other mechanisms and procedures to ensure its full implementation. DNDi is a co-signatory of the WHO, May 2017: Joint statement on public disclosure of results from clinical trials VI. Amendments DNDi retains the right to review, revise, and/or amend this document or any of its terms at its discretion at any time. When warranted and in agreement with the Chair of the Board, the Executive Director will recommend the review, revision or amendment of this document for further approval of the DNDi Board of Directors. Page 2

VII. Selected references Journal data sharing policies, for example Nature Research, 2016: Data Availability Statements and Data Citations Policy: Guidance for Authors Sherpa Juliet database of global funders who require data archiving as a condition of grants Wellcome Trust, Higher Education Funding for England, Research Councils UK, Universities UK, 2016: Concordat on Open Research Data Institute of Medicine, 2014: Discussion Framework for Clinical Trial Data Sharing: Guiding Principles, Elements and Activities Médecins Sans Frontières, 2013: MSF Data Sharing Policy WHO, May 2017: Joint statement on public disclosure of results from clinical trials Page 3

ANNEXE - Request for access to DNDi clinical data Details of requestor name institutional affiliation contact details research CV Details of dataset(s) requested nature of data request study number / identifier / title indication Details of proposed research outline proposed methodology funding sources ethical considerations approvals sought or to be sought details of collaborators, sponsor, investigator(s) and institution(s) involved lay summary expected outcomes expected duration Plans for publication of results Confirm by signing this box and describe how the Requestor commits to share data and results with DNDi Confirm by signing this box and describe how the Requestor intends to seek open-access publication